RBC Capital on Prometheus Biosciences Inc (RXDX): 'continue to see PRA023 with best-in-class potential in UC'
Tweet Send to a Friend
RBC Capital analyst Gregory Renza reiterated an Outperform rating and $111.00 price target on Prometheus Biosciences Inc (NASDAQ: RXDX).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
